Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

AI Stock Picker
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Resources

Blog
Earnings
Tutorial
Partner Program

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. JANX
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
JANX
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

JANX Similar Chart Price Prediction

The price of JANX is predicted to go up 20.63%, based on the high correlation periods with MEC. The similarity of these two price pattern on the periods is 97.11%.

stocks logo

JANX

stocks logo

MEC

Up: 20.63%Similarity: 97.11%

JANX Revenue Forecast

JANX EPS Forecast

JANX FAQs

What is bull’s view on JANX?

JANX stock closed at $43.48 on January 31, 2025, down 2.92% during regular trading and slightly lower in post-market. Analysts like Cantor Fitzgerald's Josh Schimmer maintain a bullish stance with a $200 price target, citing strong upside potential driven by innovative cancer therapies. Despite recent insider selling and mixed institutional sentiment, the bulls focus on JANX's long-term growth prospects and its proprietary T-cell engager platform.

What is bear's view on JANX?

JANX stock is currently trading at $45.15, significantly below its 52-week high of $71.71. Bearish sentiment arises from its recent cross below the 200-day moving average, signaling potential downward momentum. Additionally, insider selling by the CEO and a high put/call ratio of 3.54 reflect weak confidence and a bearish outlook.

What is JANX revenue forecast for next quarter？

The market consensus for JANX's revenue in the upcoming quarter is projected to be approximately $1.211M USD.

JANX VS S&P500

Ask Intellectia about JANX

JANX Analyst's Forecast

David Dai

UBS

Strong Buy

2024-10-24

Price Target

$69

Upside

+29.43%

UBS initiated coverage of Janux Therapeutics with a Buy rating and $69 price target. The firm launched coverage of SMID cap biotech sector with a focus in oncology and autoimmune diseases. Its top pick is Syndax. Janux has an innovative T cell engager tech "poised to make a dent" in the solid tumor treatment paradigm, the analyst tells investors in a research note.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
AI Stock PickerFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisStock Chart PatternsEarnings TradingAI Screener
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free

Hot Stocks

stocks logo

AL

Air Lease Corp

$47.63
-5.89%
stocks logo

CIVI

Civitas Resources Inc

$49.06
-3.79%
stocks logo

BIPC

Brookfield Infrastructure Corp

$42.29
-0.84%
stocks logo

AROC

Archrock Inc

$26.39
-3.05%
stocks logo

VLY

Valley National Bancorp

$9.535
-3.10%
stocks logo

SKY

Skyline Champion Corp

$100.06
-3.32%
stocks logo

MGY

Magnolia Oil & Gas Corp

$24.04
-2.28%
stocks logo

INSP

Inspire Medical Systems Inc

$177.32
-0.60%
stocks logo

SNDR

Schneider National Inc

$27.28
0.78%
stocks logo

KRG

Kite Realty Group Trust

$21.93
-1.13%